- Home
- PANW vs VRTX Comparison
PANW vs VRTX Comparison
Compare PANW & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANW
- VRTX
- Stock Information
- Founded
- PANW 2005
- VRTX 1989
- Country
- PANW United States
- VRTX United States
- Employees
- PANW N/A
- VRTX N/A
- Industry
- PANW Computer peripheral equipment
- VRTX EDP Services
- Sector
- PANW Technology
- VRTX Technology
- Exchange
- PANW Nasdaq
- VRTX Nasdaq
- Market Cap
- PANW 124.9B
- VRTX 115.6B
- IPO Year
- PANW 2012
- VRTX 1991
- Fundamental
- Price
- PANW $204.27
- VRTX $445.37
- Analyst Decision
- PANW Buy
- VRTX Buy
- Analyst Count
- PANW 45
- VRTX 26
- Target Price
- PANW $208.31
- VRTX $510.48
- AVG Volume (30 Days)
- PANW 4.6M
- VRTX 1.4M
- Earning Date
- PANW 08-18-2025
- VRTX 07-31-2025
- Dividend Yield
- PANW N/A
- VRTX N/A
- EPS Growth
- PANW N/A
- VRTX N/A
- EPS
- PANW 1.74
- VRTX N/A
- Revenue
- PANW $8,874,700,000.00
- VRTX $11,099,700,000.00
- Revenue This Year
- PANW $16.74
- VRTX $10.48
- Revenue Next Year
- PANW $14.13
- VRTX $10.69
- P/E Ratio
- PANW $115.27
- VRTX N/A
- Revenue Growth
- PANW 13.90
- VRTX 8.98
- 52 Week Low
- PANW $142.01
- VRTX $377.85
- 52 Week High
- PANW $208.39
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- PANW 59.92
- VRTX 45.87
- Support Level
- PANW $196.00
- VRTX $436.81
- Resistance Level
- PANW $202.89
- VRTX $451.88
- Average True Range (ATR)
- PANW 4.05
- VRTX 9.25
- MACD
- PANW 0.17
- VRTX 0.32
- Stochastic Oscillator
- PANW 66.51
- VRTX 28.02
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.